Mankind also has the most well-rounded therapeutic mix among peers, with strong brands across therapies. Its top-25 brands are still priced...

The company has for the last five years been ranked number one in the number of prescriptions. Manforce condoms, oral contraceptives Prega ...

The company reported net profit of Rs 193 crore during the corresponding period of the previous year. Revenue from Operations at Rs 2,053 c...

Business: Unlike its peers, Mankind Pharma started in rural India and is now expanding to urban India. The company earns 97% of its revenue...

Mankind Pharma's IPO will open on April 25. Rajeev Juneja, VC & MD, shares the company's journey from starting with an initial capital of R...

The company has hired Kotak Investment Banking, Axis Capital, IIFL Securities, Jefferies and JP Morgan as book-running lead managers while ...

The company’s initial public offering comprises an offer for the sale of 4 crore equity shares by the promoters and existing investors.The ...

In the proposed offer for sale, existing investors ChrysCapital will sell about 1% stake, Capital International will sell another 6% while ...

Under the alliance, BDR Pharma will be manufacturing and marketing the product under a royalty free, limited and non-exclusive voluntary li...

Under the COVID Protection Policy, the company will contribute an amount equivalent to five years of the last drawn gross annual salary to ...

The two-month-long ad campaign will run across television channels, digital platforms, and outdoors including hoardings and branding at pro...

The company, which is the maker of leading brands such as Manforce condoms, PregaNews and Unwanted 72, has presence in about 22 countries a...

Apax Partners & Carlyle have been shortlisted and are currently the front-runners for the proposed stake sale by Mankind Pharma, said two s...

Mankind Pharma is looking to sell a 15% stake in the company and is eyeing a premium valuation of $500-$600 mn for the same.

"Until and unless we do that, we would not be able to provide lucrative fares," SpiceJet Chief Marketing Officer Debojo Maharshi said when ...

The Delhi-based firm, which manufactures various over-the-counter products including condoms, said the new facility would produce bulk APIs.

ChrysCapital, which purchased the stake in 2007 for $24 mn will earn a 9-fold return, striking one of the largest exits in pharma sector by...